Hypersensitivity reaction to a biosimilar insulin glargine

被引：10
|
作者：
Garcia-Nares, Hector [1 ]
Leyva-Carmona, Maria Isabel [2 ]
Perez-Xochipa, Neftali [1 ]
Chiquete, Erwin [3 ]
机构：
[1] Reg Hosp 1st October, Dept Endocrinol, ISSSTE, Mexico City, DF, Mexico
[2] Reg Hosp 1st October, Dept Immunol, ISSSTE, Mexico City, DF, Mexico
[3] Salvador Zubiran Natl Inst Med Sci & Nutr, Dept Neurol, Mexico City, DF, Mexico
来源：
JOURNAL OF DIABETES | 2015年 / 7卷 / 02期
关键词：
ALLERGY; ANALOGS; LISPRO;
D O I：
10.1111/1753-0407.12241
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：155 / 157
页数：3
相关论文
共 50 条
  • [1] Biosimilar Glargine Insulin: Implications for Prescribers and Patients
    Pereira, Katherine
    [J]. JNP-JOURNAL FOR NURSE PRACTITIONERS, 2017, 13 (03): : 236 - 237
  • [2] The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn
    Matli, Mark C.
    Wilson, Andrea B.
    Rappsilber, Leah M.
    Sheffield, Farron P.
    Farlow, Miranda L.
    Johnson, Jeremy L.
    [J]. JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2023, 17 (02): : 490 - 494
  • [3] Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market
    Levy, Joseph
    Chowdhury, Zahra M.
    Socal, Mariana P.
    Trujillo, Antonio J.
    [J]. JAMA INTERNAL MEDICINE, 2021, 181 (10) : 1405 - +
  • [4] Insulin-glargine/insulin-glulisine/insulin-lisproType III hypersensitivity reaction: case report
    [J]. Reactions Weekly, 2017, 1662 (1) : 210 - 210
  • [5] Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
    Tarigan, Tri Juli Edi
    Dwijayanti, Adisti
    Setyowati, Susie
    Louisa, Melva
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2021, 14 : 107 - 116
  • [6] Implementation of biosimilar uptake: a cost minimization study for insulin glargine
    Mehring, M.
    Heim, A.
    Peyrol, C.
    Pages, A.
    Bouothmani, A.
    McCambridge, C.
    Cestac, P.
    Mange, A. -S.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 372 - 372
  • [7] A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
    Belhekar, Mahesh N.
    Pai, Sarayu
    Tayade, Parimal
    Dalwadi, Pradip
    Munshi, Renuka
    Varthakavi, Prema
    [J]. INDIAN JOURNAL OF PHARMACOLOGY, 2015, 47 (02) : 227 - 229
  • [8] Insulin glargine and hypersensitivity reactions as an example of biosimilars pharmacovigilance
    Ali, Ayad K.
    Bohm, Martin S.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 22 - 22
  • [9] LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union
    Altman, Jean-Jacques
    Chevalier, Nicolas
    Delemer, Brigitte
    Travert, Florence
    Benabbad, Imane
    [J]. PRESSE MEDICALE, 2018, 47 (10): : 854 - 866
  • [10] Insulin Access Enhancement in India: Expert Views on Integrating Interchangeable Biosimilar Insulin Glargine
    Kumar, K. M. Prasanna
    Chowdhury, Subhankar
    Bantwal, Ganapathi
    Unnikrishnan, A. G.
    Kalra, Sanjay
    Aggarwal, Sameer
    Singh, Awadhesh Kumar
    Pandit, Kaushik
    Shukla, Rishi
    Vishwanathan, Vijay
    Khobragade, Kunal
    Sarda, Prashant S.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
12345